(Fused)benz(thio)amides

Abstract: A novel (fused) benz(thio)amides of the general formula: (wherein, symbol A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethynylene group optionally being substituted by one, two or three of straight or branched alkyl group(s) of from 1 to 10 carbon atom(s) and/or phenyl group(s). Symbol B represents (i) a carbocyclic ring of from 4 to 8 members being unreplaced or replaced one, two or three of optional carbon atom(s) by oxygen, nitro and/or sulphur atom(s). (The ring may optionally be substituted by group(s) of oxo, thioxo and/or hydroxy group(s).) or (ii) a dibalent group of formula: Symbol T represents an oxygen atom or a sulphur atom. R¹ represents a group of general formula:

Description: Summary This invention is related to novel fused aminophenyl derivatives having an antagonistic activity on leukotrienes (SRS); processes for the preparation thereof; and pharmaceutical agent containing same as active ingredient. Background In the study of prostaglandins (abbreviated as PG hereafter), many important discoveries have been made continuously in recent years. And so it was found a large change in the direction of the research and development of PG. In the compounds which have been newly found or newly confirmed their structure in PG family, it can be said that PG endoperoxides, (i.e. PGG₂ and PGH₂), thromboxane A₂ (abbreviated as TXA₂ hereafter), prostacyclin (i.e. PGI₂) and leukotriene C₄, D₄ and E₄ (abbreviated as LTC₄, LTD₄ and LTE₄, respectively, hereafter) etc. have especially strong and unique biological activities. All the compounds of PG family containing various PG previously known well in addition to the above compounds, are biosynthesized from the same mother compound, i.e. arachidonic acid in a living body and, therefore, the metabolic routes starting from arachidonic acid is called "Arachidonate cascade" as a whole. The detailed explanation of each route and the pharmacological character of each metabolite are described in Igaku No Ayumi, 114 , 378 (1980), ibid , 114 , 462 (1980), ibid , 114 , 866 (1980), ibid , 114 , 929 (1980), Gendai Iryo, 12 , 909 (1980), ibid , 12 , 1029 (1980), ibid , 12 , 1065 (1980) and ibid , 12 , 1105 (1980) etc. The arachidonate cascade can be largely divided into two routes; one is the route that cyclooxygenase acts on arachidonic acid to convert, into various PGs, e.g. prostaglandin F₂ (abbreviated PGF₂ hereafter), prostaglandin E₂ (abbreviated PGE₂ hereafter), PGI₂, TXA₂, via PGG₂ and further PGH₂ and the other is the route that lipoxygenase acts on arachidonic acid to convert, in hydroxyeicosatetraenoic acid (abbreviated as HETE hereafter) or leukotrienes, via hydroperoxyeicosatetraenoic acid (abbreviated HPETE hereafter). As the former route is well known, it is not described in the present specification in detail. See Prostaglandin (1978), edited by Makoto Katori et al., published by Kohdan-sha. Concerning the latter route, it has been known that various compounds are produced according to the following scheme I. Besides being metabolized through a well known route, i.e. the route via PG endoperoxides, arachidonic acid is also metabolized through another route by the action of lipoxygenase. That is to say, arachidonic acid is metabolized by the action of lipoxygenase, e.g. 5-lipoxygenase, 12-lipoxygenase and 15-lipoxygenase, to 5-HPETE, 12-HPETE and 15-HPETE, respectively. These HPETE are converted into 5-HETE, 12-HETE and 15-HETE, respectively, by the action of peroxidase converting a hydroperoxy group into a hydroxy group. Furthermore, LTA₄ is also produced from 5-HPETE by dehydration. LTA₄ is converted into leukotriene B₄ (abbreviated as LTB₄ hereafter) or LTC₄ enzymatically. Further, LTC₄ is converted into LTD₄ by the action of γ-glutamyl transpeptidase. Moreover, it was recently defined that LTD₄ is metabolized to LTE₄ (see Biochem. Biophys. Res. Commun., 91 , 1266 (1979) and Prostaglandins, 19 (5), 645 (1980)). Besides, SRS is an abbreviation of Slow Reacting Substance and it was named by Feldberg et al. or the substance released when perfusing cobra venom through isolated lung or incubating cobra venom with vitellus. And it was reported that the substance constricted ilem isolated from guinea pig slowly and continually (see J. Physiol., 94 , 187 (1938)). Moreover, Kellaway et al. showed the relation between SRS-A and allergic reaction from the fact that SRS-A is released when an antigen is sensitized to perfusing lung isolated from guinea pig (see Quant. J. Exp. Physiol., 30 , 121 (1940)). Brocklehurst reported that when the antigen is sensitized to a lung fragment isolated from a bronchial asthmatic whose specific antigen is defined, by an operation, histamine and SRS-A are released and strongly constrict the bronchial muscle. Since such constriction can not be prevented by an antihistaminic agent, he suggested that SRS-A is an important bronchoconstrictor in an asthmatic paroxysm (see Progr. Allergy, 6 , 539 (1962)). Since then, many reports were published, for instance, SRS-A prepared from human lung slice constrict a tracheal spiral of normal human (see Int. Arch. Allergy Appl. Immunol., 38 , 217 (1970)); when SRS-A prepared from rats is injected intravenously to guinea pig, significant increase of pulmonary resistance is observed (see J. Clin. Invest., 53 , 1679 (1974)); in addition, a subcutaneous injection of SRS-A to guinea pig, rat and monkey enhances vascular permeability (see Advances in Immunology, 10 , 105 (1969), J. Allergy Clin. Immunol., 621, 371 (1978), Prostaglandins, 19 (5), 779 (1980) etc.). Generally, the substance released by immunological reaction is called SRS-A. On the other hand, the substance released by non-immunological reaction such as calcium ionophore is called SRS. However, the above two substances have many similarities each other and, therefore, it is considered they would probably be the same substance. Further, it was confirmed that SRS or SRS-A is a mixture of LTC₄ and LTD₄. So it can be understood that the pharmacological characters of these leukotrienes are the same as those of SRS or SRS-A (see Proc. Natl. Acad. Sci. USA, 76 , 4275 (1979), Biochem. Biophys. Res. Commun., 91 , 1266 (1979), Proc. Natl. Acad. Sci. USA, 77 , 2014 (1980) and Nature, 285 , 104 (1980)). Based on result of these studies, various leukotrienes (LTC₄, LTD₄ and LTE₄, and further other leukotrienes which may be confirmed their structures in future) biosynthesized from arachidonic acid via LTA₄, are considered to be important factors relating to the appearance of allergic tracheal and bronchial diseases, allergic lung diseases, allergic shock and various allergic inflammations. The suppression of leukotrienes is useful for the prevention and/or treatment of tracheal, bronchial or lung diseases such as asthma, allergic lung diseases, allergic shock or various allergic diseases. On the other hand, arachidonic acid is released from phospholipids by the action of phospholipase, and two routes were generally accepted, namely (1) the action of phospholipase A₂ on phosphatidyl choline, and (2) the action of phospholipase C on phosphatidyl inositol to produce the 1,2-diglyceride, and the action of diglyceridelipase followed by monoglyceridelipase on it to release arachidonic acid (see Kagaku to Seibutsu (Chemistry and Biology), 21 , 154 (1983)). Also it was known that the arachidonic acid released is metabolized through two different routes i.e. (1) a metabolic route to bioactive substances e.g. prostaglandins (PGs), thromboxane A₂ (TXA₂) by cyclooxygenase, and (2) a metabolic route to bioactive substances e.g. SRS-A (Slow Reacting Substances of Anaphylaxis), hydroxyeicosatetraenoic acid (HETE) and leukotriene B₄ (LTB₄) by lipoxygenase (see Kagaku to Seibutsu (Chemistry and Biology), 21 , 154 (1983)). These metabolites are known as chemical mediators; for example, TXA₂ is a compound which has a potent activity of platelet aggregation and aorta contraction, SRS-A is a chemical mediator on asthma, LTB₄ is a chemical mediator on various inflammations (e.g. gout), and PGs are also chemical mediators on various inflammations which enhance a vascular permeability and pain, and have a vasodilative action, pyrogenetic action and chemotactic action (see Prostaglandin (1978), edited by Makoto Katori et al, published by Kohdan-sha). Arachidonic acid is converted and metabolized to various chemical mediators which play an important physiological part in the living body. And it was known that ill-balances of those chemical mediators induce various disorders. As antagonists of SRS, the groups of the compounds of general formula: (wherein from R¹ to R⁵ and R⁷ each represent a hydrogen atom, a hydroxy group, an alkyl group of from 1 to 6 carbon atom(s), an alkoxy group of from 1 to 6 carbon atom(s), an amino group, an acyl group, an acylamino group of from 2 to 6 carbon atoms, an alkenyl group of from 2 to 6 carbon atoms, a halogen atom or a phenylalkoxy group in which alkoxy have from 1 to 6 carbon atom(s); X represents a hydrocarbyl group of from 1 to 10 carbon atom(s) being optionally substituted by hydroxy group(s); A represents an oxygen atom or absense; Q represents an alkylene, alkenylene or alkynylene group of from 2 to 6 carbon atoms which may be branched; D represents a carboxy group, a 5-tetrazolyl group or carbamido-5-tetrazolyl group.) form the subject of patent applications by Fisons Co., Ltd. (see Japanese Patent Application No. 55-1273841 i.e. European Patent Publication No. 17332 or United States Patent No. 4281008.). The following compounds form the subject of patent applications by Kissei Pharmaceutical Co., Ltd, as anti-allergic agents, of the general formula: (wherein R¹ and R² each represent a hydrogen atom or an alkyl group with 1-4 carbon atoms; R³ and R⁴ each represent a hydrogen atom or may be combined together to form an additional chemical bond; X represents a hydroxyl group, a halogen atom, a straight or branched chain saturated or unsaturated alkyl group with 1-4 carbon atoms, a straight or branched chain saturated or unsaturated alkoxy group with 1-4 carbon atoms, an acyloxy group with 1-4 carbon atoms, or a cycloalkyl group with up to 6 carbon atoms; n is zero or an integer of 1-3 with the proviso that when n is 2 or 3; X's may be the same or different and that when two X's are commonly the alkyl or alkoxy group, both X's may be combined together to form a ring; and Y represents a straight or branched chain alkylene group or a straight or branched chain oxyalkylene group connected to the benzene nucleus through an oxygen atom.) as well as physiologically acceptable salts thereof. (see United States Patent No. 4,026,896.) Disclosure of the Invention The present inventors have synthesized novel compounds of the general formula (I) depicted hereafter, which have a structure characterized by a (thio)amido group being substituted on fused benzene ring or benzene ring and have found that the compounds have a potent antagonistic activity on leukotrienes (SRS). The compounds of the present invention also inhibit phospholipase, so inhibit release of arachidonic acid from phospholipids, and are therefore useful for the prevention and/or treatment of diseases induced by arachidonate metabolites e.g. TXA₂, PGs, leukotrienes in mammals including human beings, especially human beings. Examples of the diseases to the subject are various allergic diseases induced by leukotrienes described above, thrombosis e.g. one induced by injury (damage) of cerebal or coronary, endothelium or intima and inflammations e.g. arthritis, rheumatism (see Junkan Kagaku (Cardiovascular Science) 3 , 484 (1983) Yakkyoku (Pharmacy) 34 , 167 (1983)). According to the present invention, there is provided a fused aminophenyl derivative of the general formula: [wherein symbol A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethylene group optionally being substituted by one, two or three straight or branched alkyl groups(s) of from 1 to 10 carbon atom(s) and/or phenyl groups(s), symbol B represents a carbocyclic ring of from 4 to 8 members wherein one, two or three of the carbon atom(s) may be replaced by oxygen, nitrogen and/or sulphur atom(s), or wherein the ring may optionally be substituted by group(s) of oxo, thioxo and/or hydroxy group(s), symbol T represents an oxygen atom or a sulphur atom, R¹ represents a group of formula: (i) (ii) or (iii) or (iv) a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s), (wherein R⁵ and R⁶ independently represent a hydrogen atom or a halogen atom or a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s) wherein one, two, three, four or five of the carbon atom(s) may be replaced by oxygen atom(s), sulphur atom(s), halogen atom(s), nitrogen atom(s), benzene ring(s), thiophene ring(s), naphthalene ring(s), carbocyclic ring(s) of from 4 to 7 carbon atom(s), carbonyl group(s), carbonyloxy group(s), hydroxy group(s), carboxy group(s), azido group(s) and/or nitro group(s)), R² represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), R³ represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: -COOR⁷ (wherein R⁷ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s)) or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s), and R⁴ represents a group of general formula: -U-(CH₂) n -COOR⁸ -U-(CH₂) p -COOR⁸ or (wherein symbol U represents an oxygen atom or a sulphur atom, R⁸ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), n and m represent an integer of from 1 to 10, respectively, and p and q represent zero or an integer of from 1 to 10, respectively)]; or a non-toxic salt thereof. The compounds of the general formula (IA) are novel, in chemical structure, because they have (thio) amido group as well as benzene ring(s) and/or chromon skeleton as the essential group, compared with the compounds of Fisons of the general formula (A), described hereinbefore in the part of background. In the general formula (I), example of the groups represented by R⁵ and R⁶ are as follows:- a hydrogen atom, a halogen atom an alkyl group of from 1 to 20 carbon atom(s) an alkenyl or alkynyl group of from 2 to 20 carbon atoms an alkoxy or alkylthio group of from 1 to 19 carbon atom(s) an alkenyloxy, alkenylthio, alkynyloxy or alkynylthio group of from 3 to 19 carbon atoms an alkyl group of from 1 to 19 carbon atom(s) being substituted by halogen atom(s) and/or hydroxy group(s) an alkenyl or alkynyl group of from 2 to 19 carbon atoms being substituted by halogen atom(s) and/or hydroxy group(s) an alkoxy or alkylthio group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s) and/or hydroxy group(s) an alkenyloxy, alkenylthio, alkynylthio or alkynyloxy group of from 3 to 18 carbon atoms being substituted by halogen atom(s) and/or hydroxy group(s) an alkyloxyalkyl, alkenyloxyalkyl or alkyloxyalkenyl group of from 2 to 19 carbon atoms a cycloalkyl, cycloalkyloxy or cycloalkylthio group of from 4 to 7 carbon atoms a phenyl, phenoxy or phenylthio group an alkyl group of from 1 to 19 carbon atom(s) which has carbocyclic ring(s) of from 4 to 7 carbon atoms, benzene ring(s), naphthalene ring(s) or thiophene ring(s) in the middle or at the terminal thereof an alkoxy, alkylthio, alkenyloxy, alkenylthio, alkynyloxy or alkynylthio group of from 1 to 18 carbon atom(s) which have carbocyclic ring(s) of from 4 to 7 carbon atoms, benzene ring(s), naphthalene ring(s) or thiophene ring(s) in the middle or at the terminal thereof a phenylthioalkoxy or phenyloxyalkyloxy group wherein alkyl moiety is a group from 1 to 17 carbon atom(s) a carboxyalkyloxy, alkoxycarbonylalkyloxy group of from 2 to 19 carbon atoms an alkoxycarbonyloxyalkyloxy group of from 3 to 19 carbon atoms an alkenylcarbonyloxy group of from 3 to 20 carbon atoms an alkylcarbonyl group of from 2 to 20 carbon atoms an azidoalkyl, nitroalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl group of from 1 to 19 carbon atom(s) an azidoalkyloxy, nitroalkyloxy, aminoalkyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy group of from 1 to 18 carbon atom(s) an alkenylcarbonylamino group of from 3 to 19 carbon atoms an alkylamino group of from 1 to 19 carbon atom(s) groups described above being further substituted by halogen atom(s), hydroxy group(s), azido group(s), nitro group(s) and/or carboxy group(s) Among the groups described above, preferable groups as R⁵ and R⁶ are the following groups: a hydrogen atom a halogen atom a straight or branched alkyl group of from 1 to 20 carbon atom(s) a straight or branched alkoxy group of from 1 to 19 carbon atom(s) a straight or branched alkenyloxy group of from 3 to 19 carbon atoms a straight or branched alkynyloxy group of from 3 to 19 carbon atoms a straight or branched alkylthio group of from 1 to 19 carbon atom(s) a straight or branched alkyl group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s) a straight or branched alkyloxyalkyl group of from 2 to 19 carbon atom(s) a cycloalkyl, cycloalkylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)) or cycloalkylalkyloxy (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)) group optionally being substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s), hydroxy group(s) halogen atom(s) and/or nitro groups(s) a phenyl, phenylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkyloxy (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)) or phenylalkenyloxy (wherein alkenyl moiety is a group of from 2 to 8 carbon atom(s)) group optionally being substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s),hydroxy group(s), halogen atom(s) and/or nitro group(s) a naphthyl, naphthylalkyl (wherein alkyl moiety is a group from 1 to 8 carbon atom(s).), naphthylalkoxy (wherein alkyl moiety is a group from 1 to 8 carbon atom(s).) or naphthylalkenyloxy (wherein alkenyl moiety is a group from 2 to 8 carbon atoms.) group optionally being substituted by straight or branched alkyl group(s), hydroxy group, halogen atom(s) and/or nitro group(s) a straight or branched alkoxy, alkenyloxy or alkyloxyalkyloxy group of from 1 to 18 carbon atom(s) being substituted by carbonyl, carbonyloxy and/or hydroxy group(s) a straight or branched alkoxy group of from 1 to 17 carbon atom(s) being substituted by phenoxy or phenylthio group(s) a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s) a straight or branched alkyl, alkenyl, alkoxy or alkenyloxy group of from 1 to 18 carbon atom(s) being substituted by azido or nitro group(s) or amino group(s) being optionally substituted by an alkyl group of from 1 to 6 carbon atom(s) (including dialkylamino group(s)) a straight or branched alkyl, alkenyl, alkoxy or alkenyloxy group of from 1 to 18 carbon atom(s) being replaced by two kinds groups which are carbonyl group(s) and amino group(s) An alkyl group of from 1 to 20 carbon atom(s) in the present invention means a group of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicocyl group and an isomeric group thereof. An alkenyl and alkynyl group of from 1 to 20 carbon atom(s) mean corresponding groups described above. An alkyl group of from 1 to 6 carbon atom(s) in the present invention means a group of methyl, ethyl, propyl, butyl, pentyl, hexyl group and isomeric group thereof. A cycloalkyl group of from 4 to 7 carbon atoms in the present invention means a group of cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl group. A halogen atom in the present invention means an atom of chlorine, bromine, iodine and fluorine atom. In the present invention, when a certain carbon atom is replaced by another atom, a ring or a group, any carbon atom(s) can be replaced, so far as the replacement per se can be acceptable in a chemical or physical sense. For example, "an isobutyl group replaced by a benzene ring in the middle or at the terminal" means a group of isopropylphenyl, dimethylphenylmethyl or 2-phenylpropyl group. When the replacement, hydrogen atom(s) may be added or removed suitably. For example, "a pentyl group replaced by a nitrogen atom at the 2nd position" means N-propylaminomethyl group. For example, 2-(phenoxy)ethoxy group and 5-(2-chloro-4-nitrophenylthio)-5-methylpent-2-enyloxy groups are induced by replacing five times or not more of them from a pentyl group and a 6,8-dimethylnon-3-enyl group, respectively, and therefore they are included in the present invention. These examples are not intended to limit the present invention. Examples of carbocyclic rings of from 4 to 8 members being unreplaced or replaced one, two or three of optional carbon atom by oxygen, nitrogen and/or sulphur atom(s) (the ring may optionally be substituted by group(s) of oxo, thioxo and/or hydroxy group(s)) represented by the symbol B in the general formula (I) are following :- (The rings above described may optionally be substituted by hydroxy group(s).) The carbocyclic rings depicted above may be saturated rings or unsaturated ones, or aromatic rings or non-aromatic ones. Any rings depicted above are preferable. And, when the rings are fused with benzene rings, the following fused benzene rings are especially preferable, i.e. the rings of the general formula: are the following rings: Process for the Preparation (1) The present invention includes not only the compounds per se , non-toxic salts thereof, use or method, but also process for the preparation. According to the present invention, the compounds of the present invention of the general formula (I) may be prepared by reacting a compound of general formula: R¹-A-COOH (II) (wherein all the symbols have the same meaning as described hereinbefore.) or a corresponding dithioic acid and a compound of general formula: (wherein all the symbols have the same meaning as described hereinbefore.) to form amide-bond, and further subjecting saponification or and/or esterification, if desired. Reactions to form amide-bond are well known, it may be carried out, for example; (A) by the method with using mixed acid anhydride (B) by the method with using acid halide (C) by the method with using DCC Concrete description of the methods described above are as follows: (A) a method using a mixed acid anhydride may be carried out, for example; an acid of the general formula (II) is reacted with an acid halide (pivaloyl chloride, thionyl chloride, tosyl chloride, mesyl chloride, oxalyl chloride etc.) or an acid derivative (ethyl chloroformate, isobutyl chloroformate etc.) in an inert organic solvent (chloroform, methylene chloride, diethyl ether, THF etc.) or without solvents, in the presence of a tertiary amine (pyridine, triethylamine, picoline etc.), at from 0°C to 40°C to give a mixed acid anhydride. The obtained mixed acid anhydride and an amine of the general formula (III) are reacted in an inert organic solvent (described above), at from 0°C to 40°C. (B) a method using an acid halide may be carried out, for example; an acid of the general formula (II) is reacted with an acid halide (described above) in an inert organic solvent (described above) or without solvents at from -20°C to a refluxing temperature of the solvent used to give an acid halide. The obtained acid halide and an amine of the general formula (III) are reacted in an inert organic solvent (described above) in the presence or absence of a tertiary amine (described above) at from 0°C to 40°C. (C) a method using DCC may be carried out, for example; an acid of the general formula (II) and an amine of the general formula (III) are reacted in an inert organic solvent (described above) or without solvents in the presence or absence of an tertiary amine (described above) using DCC at from 0°C to 40°C. Preferably, the reactions (A), (B) and (C) described above are carried out in an atmosphere of inert gas (argon, nitrogen, etc.) under anhydrous conditions. Process for the Preparation (2) Among the compounds of the present invention, compounds of the general formula: (wherein R²⁰ represents methylene group or a single bond, and the other symbols are the same meaning as described hereinbefore.) may be prepared by reacting a compound of the general formula: (wherein all the symbols have the same meaning as described hereinbefore.) with an azide. Reactions to induce a 2-tetrazolyl group from a cyano group with an azide are known, it may be carried out, for example; under anhydrous conditions, using an azide (sodium azide, lithium azide, potassium azide etc.), in the presence of a weak acid (pyridium chloride, ammonium chloride, dimethylaniline hydrochloride etc.) in an inert organic solvent (dimethylformamide, N-methylpyrrolidone etc.) with heating. Process for the Preparation (3) Among the compounds of the present invention, compounds of the general formula: (wherein R⁵⁵ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), and the other symbols are the same meaning as described hereinbefore.) may be prepared by reacting a compound of general formula: (wherein all the symbols have the same meaning as described hereinbefore.) with a compound of general formula: (wherein X¹⁰ and X²⁰ represent halogen atoms respectively, and R⁵⁰ represents a straight or branched alkyl group of from 1 to 6 carbon atom(s), and the other symbols have the same meaning as described hereinbefore.) and further, effecting esterification and/or saponification, if desired. Reactions to form a benzodioxan ring from catechol are known, and they may be carried out, for example; under anhydrous conditions, in the presence of condensing agent (potassium, carbonate,sodium carbonate etc.) in an inert organic solvent (acetone, methyl ethyl ketone, dioxane etc.), with heating Process for the Preparation (4) Among the comounds of the present invention of the general formula (I), certain compounds may be prepared from the corresponding compounds of the present invention. For example, reaction may be carried out in the following reaction formula and reaction scheme [A] (in the above case, butadienylene and butenylene groups, or groups being substituted by an alkyl or phenyl groups may also be carried out similarly, instead of a vinylene group.) (wherein the symbol represents whole group of the substituent R¹ and symbols therein are included in R¹ respectively. R¹ and groups in R¹ have the same meaning as described above in the following schemes. R³⁰ represents an alkyl, alkenyl or alkynyl group of from 1 to 18 carbon atom(s).) Each symbol in the scheme [A] represents the following meanings or as defined hereinbefore respectively. R⁴⁰,R⁴¹ - an alkyl, alkenyl or alkynyl group of from 1 to 18 carbon atom(s) R⁴⁵ - a hydrogen atom or an alkyl, alkenyl or alkynyl group of from 1 to 18 carbon atom(s) T¹⁰ - an oxygen atom or a sulphur atom, or an imido group M¹⁰ - a lithium, potassium or sodium atom X¹ - a halogen atom Processes for the Preparation of Intermediates Intermediates described hereinbefore of the general formula (III), (IV), (V) and (XXXXV) may be prepared by the processes described in the following reaction schemes, respectively. Each symbols in the schemes represent the following meanings or as described hereinbefore, respectively. R²¹ - a straight or branched alkyl group of from 1 to 6 carbon atom(s) R⁵¹,R⁵²,R⁵³,R⁵⁶ - a straight or branched alkyl group of from 1 to 6 carbon atom(s) R⁵⁴ - a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s) R⁷⁰,R⁷¹ - a trifluoroacetyl group X³⁰,X⁴⁰,X⁵⁰ - a halogen atom R¹²²,R¹⁸⁰ - a straight or branched alkyl group of from 1 to 6 carbon atom(s) R¹²⁵ - a group of formula: -U-(CH₂) n - or -(CH₂) p -(wherein all the symbols are the same meaning as described hereinbefore.) R¹⁵⁰ - a trifluoroacetyl group X¹²⁰,X¹³⁰,X¹⁴⁰,X¹⁵⁰ - a halogen atom When imino group(s) are included in the symbol B, it is preferable to protect by trifluoro group(s) etc., and to remove the protect group(s) in a suitable step. And compounds of the general formula (IIIj) may be prepared by the same procedure as the method to obtain compounds of general formula (IIIh) from compounds of general formula (IIIg). Intermediates of 1,4-dithianaphthalene skelton also may be prepared using with a compound of general formula: (Wherein all the symbols are as the same meaning as described hereinbefore.) which may be obtained by hydrolizing a compound of general formula: (wherein all the symbols are as the same meaning as described hereinbefore.) instead of the compound of the general formula (XIII). In the processes for the preparation of the compounds of the present invention, esterification and saponification may be carried out as follows. Conversion of a certain acid into a corresponding ester (i.e. esterification) is known reaction per se , and it may be carried out, for example; (1) by the method using a diazoalkane (2) by the method using an alkyl halide (3) by the method using DMF-alkylacetal and (4) by the method reacting with a corresponding alkanol Concrete descriptions of the reactions above mentioned are as follows:- (1) the method using a diazoalkane may be carried out, for example, in an inert organic solvent (diethyl ether, ethyl acetate, methylene chloride, acetone, methanol, ethanol etc.) using with corresponding diazoalkane. (2) the method using an alkyl halide may be carried out, for example, in an organic solvent (acetone, N,N-dimethylformamide, DMSO etc.), in the presence of a base (potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium oxide etc.) using with a corresponding alkyl halide. (3) the method using DMF-dialkylacetal may be carried out, for example, in an inert organic solvent (benzene, toluene etc.) using with a corresponding DMF-dialkylacetal. (4) the method reacting with a corresponding alkanol may be carried out, for example, in a corresponding alkanol, using with an acid (hydrochloric acid, sulphuric acid, p-toluenesulphonic acid, hydrochloride gas etc.) or condensing agent (DCC, pivaloyl chloride, arylsulphonyl halide, alkylsulphonyl halide etc.). Reactions mentioned above are carried out generally at from -10°C to 100°C; and they may be carried out further addition of inert organic solvent(s) (THF, methylene chloride etc.) not related to the reactions. Conversion of a certain ester into corresponding acid (i.e. saponification) is known reaction per se , and it may be carried out, for example; (1) using with an aqueous solution of an alkali (potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate etc.) in a water-miscible organic solvent (THF, dioxane, ethanol, methanol etc.). (2) using an alkali mentioned above, in an alkanol (methanol, ethanol etc.) in anhydrous condition. The reactions above are carried out generally at from -10°C to 100°C. In each reaction in the present invention, products may be purified by conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reactions, or after a series of reactions. Starting Materials Starting materials and reagents in the present invention are known compounds per se or may be prepared by known methods per se . For example, acids of the general formula (II) may be prepared by the methods described in the specification of Japanese Patent Application Nos. 58-203632, 58-224067, 58-245531, 58-245532 or 59-1855. A certain compound of the general formula (VIII) wherein R³ is a hydrogen atom is described in J. Med. Chem., 8 , 446 (1965). A certain compound of the general formula (XIII) wherein R³ is a hydrogen atom is described in J. Am. Chem. Soc., 75 , 3277 (1953). The compounds of the general formula (XV) may be prepared by the method described in J. Med. Chem., 20 , 371 (1977). A certain compound of the general formula (XXXI) wherein R³ is a hydrogen atom is described in J. Org. Chem., 42 , 1925 (1977). The compounds of the general formula (XXXXVIII) may be prepared from the compounds of the general formula (II). Compounds of the general formula (XXXXVI), (XXXXVII) and (XXXXVIII) are known compounds per se , or may be prepared by known methods per se . For example, compounds wherein the symbol B is a morpholine ring, compounds wherein the symbol B is 2,3,4,5-tetrahydrofuran, compounds wherein the symbol B is a hydroxypyridine ring, compounds wherein the symbol B is 3,4,5,6-tetrahydro-2H-pyran ring may be prepared by the methods described in J. O. Chem., 32 , 4155 (1967), Chem. Abst. 98 , 179352 q (1983), J. O. Chem., 32 , 4155 (1967), and Chem. Abst., 84 , 58747z, respectively or similar methods thereof. Salts The compounds of the present invention of the general formula (I) may be formed salts at the carboxy or tetrazolyl moiety. By converting into salts, solubility of the compounds of the present invention against water can be increased, and therefore be useful at the administration as pharmaceuticals. The compounds of the present invention may easily be converted into corresponding salts by the methods known per se , e.g. methods described hereafter. The salts in the pretent invention are preferably non-toxic ones. The non-toxic salts herein referred mean salts of cations such that it is relatively innoxious to living body (animals including human beings) tissues and that the effective pharmacological properties of the compounds of the general formula (I) are not impaired by side effect(s) resulting from the cations when used in an amount required for the prevention and/or treatment. And water-soluble salts are preferable. Suitable salts include, for example, a salt of an alkali metal such as sodium, potassium, a salt of an alkaline metal such as calcium, magnesium, an ammonium salt and a pharmaceutically acceptable (non-toxic) amine salt. Amines suitable for forming such salts with carboxylic acid or tetrazolyl group are well known and include, for example, those amines which are theoretically obtained by substituting one or more of hydrogen atom(s) of ammonia by other group(s). These groups, which may be the same or different when one or more hydrogen atom(s) are substituted, are selected from, for example, alkyl group(s) of from 1 to 6 carbon atom(s) and hydroxyalkyl group(s) of from 1 to 3 carbon atom(s). Suitable non-toxic amine salts include salts of a tetraalkylammonium group, such as tetramethylammonium salt and salts of an organic amine, such as methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, lysine and arginine Salts can be obtained from the compounds of the present invention of the general formula (I), by methods known per se , for example, by reacting the compound of the general formula (I) and a suitable base such as a hydroxide or carbonate of an alkali metal or alkaline earth metal, ammonium hydroxide, ammonia or an organic amine in theoretical amounts in an appropriate solvent. The salts can be isolated by freeze-drying the solution, or by filtration if the salts are sufficiently insoluble to the reaction solution, or if necessary, by removing part of the solvent followed by filtration. Pharmaceutical Activities The compounds of the present invention possess an antagonistic activity on leukotrienes. In a standard laboratory test, for example, the compounds of the present invention showed the pharmaceutical activity in the following tables. The compounds of the present invention showed an antagonistic activity on LTD₄ in vitro (method is described hereafter), shown in the following tables. As is obvious from the table I and II, compounds of 1,4-benzodioxan skeleton having any substituent R, represented by the general formula (IA') or (IA'') among the compounds of the present invention (i.e. the case that the symbol B and R⁴ are fixed and R¹ and A are changed in the general formula (I).) have enough activity for pharmaceutical use. And from the table III, it is confirmed if alkylene moiety (corresponding to the symbol A in the general formula (I).) would be converted, compounds having the enough pharmaceutical activity are given. In the following tables, the comparision of activity by skeleton changes are shown. And further, from the table IV, V and VI, it can be clear that compounds replaced its skeleton to various rings also possess enough activity compared with the compounds having 1,4-benzodioxan skelton (i.e. the case that R¹ and the symbol A are fixed and the symbol B and R⁴ are changed.). According to the points above described, it is estimated fairly that replacement of an essential skeleton of a certain compound from 1,4-benzodioxan to various rings and/or change of the groups of general formula: R¹-A- in the general formula (I) also lead a compound having enough activity for pharmaceutical use. From the arguments above described, it is fully expected that all extent of the present invention have effective activity and therefore be useful for pharmaceutical agent. Antagonistic activity of the compounds of the present invention on LTD₄ were measured by the following method. A segment of ilem (2.5 cm) was removed from guinea pig 300 - 400 g and suspended in a Magnus tube containing Tyrodes solution. The tube was maintained at 37°C and aerated with 95% O₂ - 5% CO₂. After stabilizing from 30 mins, 5 x 10⁻⁹ g/ml of LTD₄ was added to the Magnus tube. Contraction length at the time and contraction lengths when the compounds of the present invention were challenged at some concentrations were measured, and the IC₅₀ value were calculated. Toxicity On the other hand, it was confirmed that the acute toxicity (LD₅₀) of all extent of the present invention were more than 500 mg/kg animal body weight by intravenous administration. Therefore, the compounds of the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use. For example, the values of LD₅₀ of the compounds prepared in example 1(76), 1(212), 1(230) and 1(247) were more than 1000 mg/kg animal body weight by intravenous administration in male mice weighing 170 - 180g, respectively. Application for Pharmaceuticals The present invention is also related to pharmaceutical agent for leukotriene antagonist. To suppress leukotrienes is useful for the prevention and/or treatment of tracheal, bronchial or lung diseases such as asthma, allergic lung diseases, allergic shock or various allergic diseases in mammals including human beings, especially human beings. For the purpose hereinbefore described, the compounds of the present invention of the general formula or non-toxic salts thereof may normally be administered systemically or partially; usually by oral or parenteral administration. The doses to be administered is determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 0.1 mg and 100mg, preferably between 2 mg and 20 mg, by oral administration, up to several times per day, and between 10 ug and 10 mg, preferably between 0.1 mg and 1 mg, by parenteral administration up to several times per day. As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used. Solid compositions according to the present invention for oral administration include compressed tablets, dispersible powders and granules. In such solid compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium metasilicate aluminate. The compositions may also comprise, as is normal practice, additional substances other than inert diluents e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium gluconate, and assistant for dissolving e.g. arginine, glutamic acid or amino-acid such as aspartic acid. The tablets or pills may, if desired, be made into gastric film-coated or enteric film-coated tablets or pills, such as sugar-coated, gelatin-coated, hydroxypropyl cellulose-coated or hydroxypropylmethyl cellulose phthalate-coated tablets or pills; two or more of layers may be used. The compositions for oral administration also include capsules of absorbable material such as gelatin. Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as distilled water or ethanol. Besides inert diluents such compositions may also comprise adjuvants such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents. Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Preparations for injection according to the present invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions. Example of aqueous solvents or suspending media are distilled water for injection and physiological salt solution. Examples of non-aqueous solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, POLYSORBATE 80 (registered Trade Mark). These compositions may also include adjuvants such as preserving, wetting, emulsifying, despersing agents and assistant agent for dissolving (e.g. arginine, glutamic acid or amino-acid such as aspartic acid). They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use. Other compositions for parenteral administration include liquids for external use, and endermic liniments such as ointments, suppositories and pessaries which comprise one or more of the active compound(s) and may be prepared by known methods. Nomenclature and excluding compounds Throughout the specification including claims, the compounds of the present invention are named as derivatives having the following fused benzene rings or benzene ring. And throughout the specification including claims, isomers generated by the existence of stereo configuration unlimited (e.g. asymmetric carbon, double bond) are included in the corresponding formula, respectively. With proviso that, compounds which cannot exist per se in a chemical or physical sense (e.g. ones having multiple bond next to an oxygen, nitrogen or sulphur atom.) are excluded from the present invention. Reference Examples and Examples The following reference examples and examples are illustrate the present invention, but not limit the present invention. In the reference examples and examples, "TLC", "NMR", "IR" and "Mass" represent "Thin layer chromatography", "Nuclear magnetic resonance spectrum", "Infrared absorption spectrum" and "Mass spectrum", respectively. The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations. Unless otherwise specified, "IR" was measured by the KBr tablet method and "NMR" was measured in a mixture of chloroform-d and ethanol-d₄ respectively. Reference example 1 Synthesis of 3-(m-methoxy-p-pentyloxycinnamoyl)aminopyrocatechol Oxyalyl chloride (4.5 ml) was added to m-methoxy-p-pentyloxybenzoic acid (528 mg). In an atmosphere of argon, the solution was stirred for 30 min at room temperature and then concentrated under reduced pressure. The residue was dissolved into methylene chloride (10 ml). In an atmosphere of argon, the solution was dropped to a solution of 3-aminopyrocatechol (275 mg) in a mixture of methylene chloride (10 ml) and pyridine (3 ml) cooling with ice, and the solution was stirred for 1 hr at the same temperature. After stirring for 2 hrs at room temperature, the solution was poured into 1N hydrochloric acid. The mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried and concentrated under reduced pressure. Solids obtained was washed with hexane, and dried to give the title compound (700 mg) having the following physical data: TLC : Rf 0.20 (ethyl acetate: hexane = 1:2); NMR (CDCl₃): δ 10.00(1H, s), 7.75(1H, d), 7.60(1H, s), 6.30-7.25(7H, m), 6.10(1H, s), 4.10(2H, t), 1.90(3H, s); Mass: m/e 371(M⁺), 247, 177, 145, 125, 117, 89. Reference example 2 Synthesis of 8-(m-methoxy-p-pentyloxycinnamoyl)amino-1,4-dioxane-2-carbonitrile Dry potassium carbonate (770 mg) and 2-chloroacrylonitrile (0.30 ml) were added to a solution of 3-(m-methoxy-p-pentyloxycinnamoyl)aminopyrocatechol (690 ml; synthesized in reference example 1) in acetone (10 ml). In an atmosphere of argon, the mixture was refluxed for 3 hrs. The reaction mixture cooled to room temperature was poured into ice-water (50 ml). The mixture was extracted with ethyl acetate. The extract was dried, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride: ethyl acetate = 10:1) to give the title compound (565 mg) having the following physical data: TLC : Rf 0.15 (ethyl acetate: hexane = 1:2); NMR (CDCl₃): δ 8.25(1H, dd), 7.70(1H, d), 7.55(1H, s), 7.00-7.25(2H, m), 6.90(1H, d), 6.85(1H, d), 6.70(1H, dd), 6.45(1H, d), 5.20(1H, dd), 4.30-4.55(2H, m), 4.05(2H, t), 3.93(3H, s); Mass: m/e 422(M⁺), 247, 177, 145, 117. Reference example 3 (Example A) Synthesis of 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetic acid methyl ester Potassium carbonate (509 mg) was added to a solution of 3-(p-pentylcinnamoyl)aminopyrocatechol (300 mg; synthesized by the same procedure as reference example 1) and 4-bromo-2-butenoic acid methyl ester in acetone (10 ml), and the mixture was refluxed for 10 min. The reaction mixture was poured into water. The mixture was extracted with ethyl acetate. The extract was purified by column chromatography on silica gel (hexane: ethyl acetate = 5:1) to give the title compound (341 mg). Reference example 4 Synthesis of 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetamide 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetic acid methyl ester (341 mg; synthesized in reference example 3) was dissolved into ethanol which was saturated with ammonia (20 ml). The solution was allowed to stand for 3 days at 100°C. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane: ethyl acetate = 2:1) to give the title compound (191 mg). Reference example 5 Synthesis of 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetonitrile Trifluoroacetic anhydride (0.1 m) was added to a solution of 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetamide (191 mg; synthesized in reference example 4) in THF (10 ml) cooling with ice. And pyridine (0.02 ml) was added to the mixture. After stirring for 10 min, the mixture was poured into water. The mixture was extracted with ethyl acetate. The extract was dried, concentrated under reduced pressure to give the title compound. Example 1 Synthesis of 8-[p-(3Z-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane A mixture of p-(3Z-hexenyloxy)benzoic acid (110 mg) and oxalyl chloride (1 ml) was stirred for 1 hr at room temperature. From the mixture, excess oxalyl chloride was removed under reduced pressure. The residue was dried in vacuo, and then dissolved into methylene chloride (2 ml). In an atmosphere of argon, the solution was dropped into a solution of 8-amino-2-(5-tetrazolyl)-1,4-benzodioxane hydrochloride (128 mg) in a mixture of methylene chloride (2 ml) and pyridine (0.7 ml). The solution was stirred for 5 hrs at room temperature. The solution was diluted with ethyl acetate. The diluted solution was poured into 1N hydrochloric acid (1 ml). The mixture was extracted with ethyl acetate. The extract was washed with water, dried, and concentrated under reduced pressure. The residue was recrystalized from benzene to give the title compound (112 mg) having the following physical data: TLC : Rf 0.57 (chloroform: methanol = 3:1); NMR : δ 7.90(2H, d), 7.88(1H, m), 7.46(1H, dd), 6.96(2H, d), 6.92(1H, t), 6.78(1H, dd), 5.77(1H, dd), 5.70(2H, m), 4.61(2H, m), 4.04(2H, t), 2.57(2H, dt), 2.12(2H, m), 1.01(3H, t); IR : ν 3600-2300, 1650, 1610, 1540, 1505, 1460, 1250, 1175, 1090, 840, 770 cm⁻¹; Mass: m/e 421(M⁺), 203; Appearance: white powder. Example 1(1) - 1(121) By the same procedure as example 1, using with a corresponding carboxylic acid and 8-amino-2-(5-tetrazolyl)-1,4-benzodioxane hydrochloride, following compounds having the following physical data, shown in table [VIII] were given Example 1(201) - 1(260) By the same procedure as example 1, using with a corresponding carboxylic acid and a corresponding 8-amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran hydrochloride which have corresponding substituent R³, following compounds having the following physical data, shown in table [IX] were given. Example 1(301) - 1(302) By the same procedure as example 1, using with p-pentylcinnamic acid and 8-amino-2-(5-tetrazolyl)-2,3-dihydro-1,4-dithianaphthalene hydrochloride or 5-amino-2-(5-tetrazolyl)-2,3-dihydro-1,4-dithianaphthalene hydrochloride, following compounds having the following physical data, shown in table [X] were given. Example 1(401) By the same procedure as example 1, using with p-heptyloxybenzodithioic acid and 8-amino-2-(5-tetrazolyl)-1,4-benzodioxane hydrochloride, following compound having following physical data was given. TLC : Rf 0.14 (chloroform: methanol = 17:3); NMR : δ 7.87(2H, d), 7.77(1H, m), 6.90(4H, m), 5.74(1H, m), 4.58(2H, m), 3.98(2H, t), 1.78(2H, m), 1.30(8H, m), 0.88(3H, t); IR : ν 3600-2400, 1600, 1495, 1450, 1255, 1170, 1090, 1005, 960, 830 cm⁻¹; Mass: m/e 453(M⁺), 420, 354, 326, 235, 219, 137, 121; Appearance: orange powder. Example 1(501)-1(526) By the same procedure as example 1, using a corresponding carboxylic acid and a corresponding amine, following compounds having the following physical data, shown in table [XI] were given. Example 2 Synthesis of 8-(3-methoxy-4-pentyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane Sodium azide (490 mg) and pyridinium chloride (870 mg) were added to a solution of 8-(3-methoxy-4-pentyloxycinnamoyl)amino-1,4-benzodioxane (560 mg; synthesized in reference example 2) in dry dimethylformamide (3 ml). In an atmosphere of argon, the solution was stirred for 1.5 hrs at 100°C. The reaction solution cooled to room temperature was poured into 1N hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried, and then concentrated under reduced pressure. The residue was recrystalized from ethyl acetate to give the title compound (390 mg) having the following physical data: TLC : Rf 0.10 (chloroform: methanol = 5:1); NMR : δ 7.69(1H, d), 7.68(1H, s), 7.05-7.25(2H, m), 6.80-7.00(2H, m), 6.74(1H, m), 6.65(1H, d), 5.73(1H, m), 4.69(1H, dd), 4.51(1H, dd), 4.05(2H, t), 3.92(3H, s), 1.87(2H, m), 1.30-1.55(4H, m), 0.94(3H, t); IR : ν 2940, 2850, 1655, 1600, 1540, 1505, 1450, 1260 cm⁻¹; Mass: m/e 465(M⁺), 247, 177, 145. Example 2(1) - 2(46) By the same procedures as reference example 1, 2 and example 1, using a corresponding carboxylic acid and 3-aminopyrocatechol, following compounds having the following physical data, shown in table [XII] were given. Example 2(101) - 2(107) By the same procedures as reference example 1, 2 and example 2, using a corresponding carboxylic acid and 3-aminopyrocatechol which have corresponding substituents R² and R³, following compounds having the following physical data, shown in table [XIII] were given. Example 2(201) - 2(204) By the same procedure as reference example 1, 2 and example 2, using with a corresponding carboxylic acid and 3-aminopyrocatechol which have corresponding substituent R³, following compounds having following physical data were given. 2(201) TLC : Rf 0.21 (chloroform: methanol = 3:1); NMR : δ 8.03(1H, d), 7.70(1H, d), 7.48(2H, d), 7.20(2H, d), 6.71(1H, d), 6.65(1H, d), 5.57(1H, s), 4.70-4.40(2H, m), 2.62(2H, t); IR : ν 3700-3000, 1680, 1625, 1610, 1535, 1470, 1440 cm⁻¹; Mass: m/e 201, 179, 162; Appearance: white powder. 2(202) (The substituting position of tetrazolyl was not known.) TLC : Rf 0.22 (methylene chloride: methanol = 5:1); NMR : δ 8.21(1H, d), 7.74(1H, d), 7.57(1H, d), 7.49(2H, d), 7.20(2H, d), 6.62(1H, d), 5.74(1H, dd), 4.89(1H, dd), 4.54(1H, dd); IR : ν 3370, 3200-2300, 1695, 1630, 1610, 1520, 1430, 1270, 1140 cm⁻¹; Mass: m/e 477(M⁺), 291, 201; Appearance: white crystal. 2(203) - 2(204) less polar compound: TLC : Rf 0.18 (methylene chloride: methanol = 5:1); NMR (CDCl₃): δ 9.88(1H, s), 7.81(1H, d), 7.45(3H, s), 7.18(2H, s), 6.69(1H, s), 6.64(1H, d), 6.04(1H, s), 5.60(1H, s), 4.50(1H, s), 3.84(3H, s), 0.88(3H, t); IR : ν 3600-2300, 1695, 1630, 1610, 1515, 1470, 1280 cm⁻¹; Mass: m/e 477(M⁺), 446, 291, 201; Appearance: white crystal. more polar compound: TLC : Rf 0.12 (methylene chloride: methanol = 5:1); NMR (CDCl₃): δ 9.44(1H, s), 7.46(1H, s), 7.25(1H, s), 7.13(2H, s), 6.88(2H, s), 6.60-6.30(2H, s), 5.20(1H, s), 4.20-3.60(2H, s), 3.72(3H, s), 0.83(3H, t); IR : ν 3600-3000, 1695, 1630-1610, 1520, 1480, 1280 cm⁻¹; Mass: m/e 477(M⁺), 446, 291, 201; Appearance: white crystal. Example 2(301) By the same procedure as example 2, using with 8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2-acetonitrile (synthesized in reference example 5), following compound having the following physical data was given. TLC : Rf 0.36 (methylene chloride: methanol = 5:1); NMR : δ 7.88(1H, d), 7.70(1H, d), 7.47(2H, d), 7.20(2H, d), 6.84(1H, t), 6.63(1H, dd), 6.57(1H, d), 3.36(2H, d); IR : ν 3300, 3200-2300, 1660, 1605, 1530, 1460 cm⁻¹; Mass: m/e 433(M⁺), 233, 201; Appearance: dark brown powder. Example 2(302)-2(303) By the same procedure as example 2, using with a corresponding nitrile, following compounds having the following physical data were given. 2(302) TLC : 0.3 (methylene chloride: methanol = 5:1); IR : ν 1655, 1615, 1600, 1540, 1490 cm⁻¹; Mass: m/e 391(M⁺), 349, 309, 217, 201, 191; Appearance: pale yellow powder 2(303) TLC : 0.22 (chloroform: methanol = 9:1); IR : ν 3300-2300, 2920, 1655, 1620, 1540, 1470, 1350, 1045, 980 cm⁻¹; Mass: m/e 407(M⁺), 324, 292, 201; Appearance: pale yellow crystal. Example 3 Synthesis of 8-(p-pentylcinnamoyl)amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester Oxalyl chloride (3.4 ml) was added to p-pentylcinnamic acid (327 mg), and the mixture was stirred for 30 min at room temperature. Excess oxyalyl chloride was removed from the mixture under reduced pressure. The residue was dissolved to methylene chloride (5 ml). In an atmosphere of argon, a solution of 8-amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester (420 mg) in a mixture of methylene chloride (5 ml) and triethylamine (0.6 ml) was added slowly. The reaction solution was stirred for 1 hr at room temperature, and then poured into 0.1N hydrochloric acid. The mixture was extracted with ethyl acetate. The extract was washed with water, a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, successively, dried, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate: hexane = 1:3) to give the title compound (140 mg) having the following physical data: TLC : Rf 0.60 (ethyl acetate: hexane = 1:1); NMR (CDCl₃): δ 8.76(1H, dd), 8.23(1H, s), 7.72(1H, dd), 7.65(1H, d), 7.38(2H, d), 7.27(1H, t), 7.07(2H, d), 7.00(1H, s), 6.52(1H, d); IR : ν 3270, 2930, 1730, 1660, 1630, 1530, 1430, 1290, 1260, 1180, 770 cm⁻¹; Mass: m/e 433(M⁺), 404, 388, 376, 360, 318, 233, 201, 131; Appearance: white powder. Example 4 Synthesis of 8-(p-pentylcinnamoyl)amino-4-oxo-4H-1-benzopyran-2-carboxylic acid 8-(p-pentylcinnamoyl)amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester (132 mg; synthesized in example 3) was dissolved into ethanol (10 ml). To the solution, an aqueous solution (1 ml) of sodium bicarbonate (126 mg) was added. The mixture was refluxed for 15 min. To the reaction solution mixture cooled to room temperature, water (20 ml) and 1N hydrochloric acid (2 ml) were added. The mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried, and concentrated under reduced pressure. The residue was washed with a mixture of ethyl acetate and hexane (1:1), and dried to give the title compound (62 mg) having the following physical data: TLC : Rf 0.25 (ethyl acetate: methanol = 5:1); NMR : δ 8.66(1H, dd), 7.86(1H, dd), 7.73(1H, d), 7.53(2H, d), 7.43(1H, t), 7.22(2H, d), 7.15(1H, s), 7.08(1H, d); IR : ν 3400, 2930, 1635, 1520, 1430, 1360 cm⁻¹; Mass: m/e 405(M⁺), 361, 201, 181, 169, 131, 69; Appearance: yellow powder. Example 4(1) - 4(3) By the same procedure as example 3 and 4, using with a corresponding carboxylic acid and 8-amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester which have corresponding substituent R³, following compounds having the following physical data, shown in table [XIV] were given. Example 4(101) - 4(104) By the same procedure as example 3 and 4, using with corresponding carboxylic acid and 8-amino-1,4-benzodioxane-2-carboxylic acid ethyl ester, following compounds having the following physical data, shown in table [XV] were given. Example 4(201)-4(208) By the same procedure as example 4, using with a corresponding carboxylic acid and a corresponding amine, following compounds having the following physical data, shown in table [XVI] were given. Example 5 Synthesis of 8-[p-(4-phenylbutoxy)benzoylamino]-2-(5-tetrazolyl)-2,3-dihydrobenzoxazin In an atmosphere of argon, a mixture of 8-[p-(4-phenylbutoxy)benzoylamino]-N-trifluoroacetyl-2,3-dihydrobenzoxazin-2-nitrile (316 mg), sodium azide (196 mg), ammonium chloride (161 mg) and dimethylformamide (2.5 ml) was stirred for 1 hr at 100°C. After reaction, the reaction solution was poured into a mixture of ice and dil. hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was washed, dried over magnesium sulphate, and condenced under reduced pressure. The residue was dissolved into ethanol which was saturated with ammonia (50 ml). The solution was stirred for 20 hrs at room temperature and then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform: methanol = 3:1) to give the title compound (207 mg) having the following physical data: TLC : Rf 0.36 (chloroform: methanol = 3:1); IR : ν 3600-2300, 1630, 1600, 1500, 1465, 1250, 1170 cm⁻¹; Mass: m/e 470(M⁺), 376, 358, 253; Appearance: brown powder. Example 5(1)-5(8 ) By the same procedure as example 5, using with a corresponding nitrile, following compounds having the following physical data, shown in table [XVIII] were given. Example 6 Synthesis of 8-[3-(p-pentylphenyl)propionyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane 8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane (216 mg; synthesized in example 2(1)) and palladium-carbon (50 mg; content 5%) were suspended in a mixed solvent (6 ml) of methanol, ethanol and ethyl acetate (1:1:1). In an atmosphere of hydrogen, the suspension was stirred for 90 min at room temperature. After stirring, the suspension was filtered through celite. The filtrate was condenced under reduced pressure. Thre residue was purified by column chromatography on silica gel (methylene chloride: methanol = 19:1) to give the title compound (202 mg) having the following physical data: TLC : Rf 0.54 (methylene chloride: methanol = 4:1); NMR (CDCl₃): δ 7.28(1H, s), 7.11(4H, 2d), 6.76(2H, m), 6.60(1H, dd), 5.68(1H, t), 4.93(1H, dd), 3.04(2H, t), 2.77(2H, m), 2.56(2H, t), 1.58(2H, m), 1.30(4H, m), 0.88(3H, t); IR : ν 3600-2300, 1650, 1615, 1530, 1460, 1260, 1100, 780 cm⁻¹; Mass: m/e 421(M⁺), 219; Appearance: white crystal. Example 7 Synthesis of 8-[p-(6-hydroxyhexyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane A 1N aqueous solution of sodium hydroxide (0.5 ml) was added to a solution of 8-[p-(6-acetyloxyhexyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane (100 mg; synthesized in example 1 (96)) in methanol (0.5 ml) at room temperature. The reaction solution was stirred for 10 min at the same temperature, and then concentrated under reduced pressure. To the residue, dil. hydrochloric acid was added and the mixture was extracted with ethyl acetate. The extract was dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride: methanol = 100:1) to give the title compound (95 mg) having the following physical data: TLC : Rf 0.23 (methylene chloride: methanol = 5:1); NMR : δ 7.89(2H, d), 7.46(1H, dd), 6.95(2H, d), 6.92(1H, t), 6.76(1H, dd), 4.02(2H, t), 3.60(2H, t); IR : ν 3400, 3200-2300, 1630, 1600, 1520, 1500, 1440, 1250 cm⁻¹; Mass: m/e 439(M⁺), 221, 149, 121; Appearance: white amorphous. Example 8 Synthesis of 8-[p-[5-(N,N-dimethylamino)pentyloxy]cinnamoyl]amino-1,4-benzodioxane sodium salt A 40% aqueous solution of dimethylamine (1 ml) was dropped to a solution of 8-[p-(5-bromopentyloxy)cinnamoyl]amino-1,4-benzodioxane (176 mg; synthesized in example 1 (113)). The solution was stirred for 1 hr at room temperature. Volatile matter was removed with vacuum pump for 1 hr at room temperature, and for 3 hrs at 90°C. The residue was dissolved into methanol (1 ml), to the solution, a 2N aqueous solution of sodium hydroxide (360 µl). The mixture was condensed under reduced pressure. To the residue, small amount of methanol and hexane (4 ml) were added. The mixture was filtered, and volatile matter was removed from the filtrate with vacuum pump overnight at room temperature and overnight at 80°C to give the title compound (179 mg) having the following physical data: TLC : Rf 0.33 (ethyl acetate: acetic acid: water = 3:1:1); NMR : δ 7.87(2H, d), 7.62(1H, dd), 6.98(2H, d), 6.86(1H, t), 6.71(1H, dd), 4.06(2H, t), 2.85(2H, t), 2.64(2H, s); IR : ν 3430, 2930, 1655, 1605, 1505, 1445, 1255 cm⁻¹; Mass: m/e 452(M⁺), 233; Appearance: white powder. Example 9 Synthesis of 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-7-carboxylic acid 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-7-carboxylic acid methyl ester (332 mg; synthesized in example 2 (107) was dissolved in methanol (1.5 ml). To the solution, a 1N aqueous solution of sodium hydroxide (1.36 ml), and the mixture was stirred for 50 min at room temperature and for 2 hrs at 40°C. After cooling, 1N hydrochloric acid (2 ml) was added to the solution. The mixture was extracted with ethyl acetate. The extract was dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform: methanol = 9:1) to give the title compound (263 mg) having the following physical data: TLC : Rf 0.15 (chloroform: methanol = 4:1); NMR : δ 8.00(2H, d), 7.68(1H, d), 6.98(2H, d), 6.82(1H, d), 6.04(1H, m), 4.56(2H, m), 4.03(2H, t), 1.82(2H, m), 1.31(10H, m), 0.88(3H, t); IR : ν 3600-2300, 1680, 1640, 1600, 1490, 1460, 1250, 1170, 1080, 900, 840, 760 cm⁻¹; Mass: m/e 495(M⁺), 477, 383, 233; Appearance: pale brown powder. Example 10 Synthesis of 8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-6-methyl-1,4-benzodioxane sodium salt 8-(p-pentylcinnamoyl)-2-(5-tetrazolyl)-6-methyl-1,4-benzodioxane (50 mg; synthesized in example 2 (103)) was dissolved in methanol (0.5 ml). To the solution, equivalent molar of a 1N aqueous solution of sodium hydroxide was added. The solution was stirred and then evaporated to dryness to give the title compound (51 mg). Example 11 By the same procedure as example 10, corresponding sodium salts of the compounds synthesized in examples (other than example 10 and esters) were given. Example 12 8-[p-(3E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane (0.5 g), cellulose calcium gluconate (200 mg; disintegrator), magnesium stearate (100 mg; lubricator) and microcrystalline cellulose (9.2 g) were admixed and punched out in conventional manner to give 100 tablets each containing 5 mg of the active ingredient.

Claims: Claims for the following Contracting States : BE, DE, FR, GB, IT, LU, NL, CH, LI, SE A fused aminophenyl derivative of the general formula: [wherein symbol A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethylene group optionally being substituted by one, two or three straight or branched alkyl groups(s) of from 1 to 10 carbon atom(s) and/or phenyl groups(s), symbol B represents a carbocyclic ring of from 4 to 8 members wherein one, two or three of the carbon atom(s) may be replaced by oxygen, nitrogen and/or sulphur atom(s), or wherein the ring may optionally be substituted by group(s) of oxo, thioxo, and/or hydroxy group(s), symbol T represents an oxygen atom or a sulphur atom, R¹ represents a group of formula: (i) (ii) or (iii) or (iv) a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s), (wherein R⁵ and R⁶ independently represent a hydrogen atom or a halogen atom or a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s) wherein one, two, three, four or five of the carbon atom(s) may be replaced by oxygen atom(s), sulphur atom(s), halogen atom(s), nitrogen atom(s), benzene ring(s), thiophene ring(s), naphthalene ring(s), carbocyclic ring(s) of from 4 to 7 carbon atom(s), carbonyl group(s), carbonyloxy group(s), hydroxy group(s), carboxy group(s), azido group(s) and/or nitro group(s)), R² represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), R³ represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: -COOR⁷ (wherein R⁷ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s)) or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s), and R⁴ represents a group of general formula: -U-(CH₂) n -COOR⁸ -U-(CH₂) p -COOR⁸ or (wherein symbol U represents an oxygen atom or a sulphur atom, R⁸ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), n and m represent an integer of from 1 to 10, respectively, and p and q represent zero or an integer of from 1 to 10, respectively)]; or a non-toxic salt thereof. A compound according to claim 1, wherein the symbol B is a ring of formula: (the rings may optionally be substituted by hydroxy group(s).) A compound according to claim 2, wherein the symbol B is 2,3,5,6-tetrahydro-1,4-dioxane ring (i.e the formula: A compound according to claim 3, wherein the symbol A is a single bond, and the symbol T is an oxygen atom. A compound according to claim 4, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). 8-(p-Heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-(p-isooctyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkenyloxy group of from 3 to 19 carbon atoms. 8-[p-(2E-Octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2Z-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-nonenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(3E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-octenyloxy)benzoyl]amino-1,4-benzodioxane-2-carboxylic acid or methyl ester thereof, 8-[p-(2E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-(p-geranyloxy benzoyl)amino-2-(5-tetrazoyl)-1,4-benzodioxane, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(2E,4E-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkynyloxy group of from 3 to 19 carbon atoms. 8-[p-(2-Octynyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(2-isooctynyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkylthio group of from 1 to 19 carbon atom(s). 8-(p-Heptylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). 8-[p-(6-Chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(5-chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(4-chlorobutoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(9-chlorononyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4 benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a phenyl, phenylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkenyloxy (wherein alkenyl moiety is a group of from 2 to 8 carbon atoms), napthyl, napthylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), napthylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s) ) or napthylalkenyloxy group (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) being unsubstituted or substituted by a straight or branched alkyl group of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). 8-[p-(p-Propylphenyl)methoxybenzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy, alkenyloxy or alkoxyalkoxy group of from 1 to 18 carbon atom(s) wherein carbon atom(s) is/are replaced by carbonyl group(s), carbonyloxy group(s) or hydroxy group(s). 8-(p-Octanoylbenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 17 carbon atom(s) being substituted by a phenoxy or phenylthio group. 8-[p-(3-Phenylthiopropoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(3-phenoxypropoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). 8-[p-[4-(2-Thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 5, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by azido group(s), nitro group(s) or amino group(s) which are unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) (including dialkylamino group). 8-[p-(5-Azidopentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 3, wherein the symbol A is a vinylene group unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group, and the symbol T is an oxygen atom. A compound according to claim 26, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A compound according to claim 27, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). 8-(p-Isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 27, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). 8-[p-(4-Chlorobutoxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(5-chloropentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 27, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkyloxyalkyl group of from 2 to 19 carbon atoms. 8-(p-Isopentyloxymethylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 27, wherein R⁵ is a hydrogen atom, and R⁶ is a phenyl, phenylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)) or phenylalkenyloxy (wherein the alkenyl moiety is a group of from 2 to 8 carbon atom(s)) being unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). 8-[p-(2-Phenylethoxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or sodium salt thereof. A compound according to claim 27, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). 8-[p-[2-(2-Thienyl)ethoxy]cinnamoyl]-amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 3, wherein the symbol A is a single bond or vinylene group, and the symbol T is a sulphur atom. 8-(p-Heptyloxybenzothioyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A compound according to claim 2, wherein the symbol B is 4-oxo-2,3-dihydro-4H-1-pyran ring (i.e. the formula: A compound according to claim 40, wherein the symbol A is a single bond, and the symbol T is an oxygen atom. A compound according to claim 41, wherein R¹ is a group of general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a hydrogen atom or a straight or branched alkyl group of from 1 to 20 carbon atom(s). 8-(p-Heptylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-octylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-(p-nonylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). 8-(p-Butoxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-6-fluoro-4-oxo-4H-1-benzopyran, 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkenyloxy group of from 3 to 19 carbon atoms. 8-[p-(2E,7-Octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-geranyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-fluoro-4-oxo-4H-1-benzopyran, 8-[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-chloro-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkynyloxy group of from 3 to 19 carbon atoms. 8-[p-(2-Octynyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran or sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). 8-[p-(5-Chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is phenyl, phenylalkyl (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s).), phenylalkenyloxy (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) naphthyl, naphthlalkyl (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), naphthylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), or naphthylalkenyloxy group (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) being unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). 8-[p-(3-Phenylpropoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(3-phenyl-2E-propenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 42, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). 8-[p-[4-(2-Thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 40, wherein the symbol A is a vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 57, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A compound according to claim 58, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). 8-(p-Isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran or sodium salt thereof. A compound according to claim 58, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). 8-[p-(5-Chloropentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-(6-chlorohexyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A compound according to claim 2, wherein the symbol B is a pyridine ring optionally substituted by hydroxy group(s) (i.e. the formula: A compound according to claim 63, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 64, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). 8-[p-(4-Phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-quinoline, or 8-[p-(4-phenylbutoxy)benzoyl]amino-4-hydroxy-2-(5-tetrazolyl)-quinoline; or a sodium thereof A compound according to claim 2, wherein the symbol B is 4,5-dihydrodioxole ring (i.e. the formula: A compound according to claim 67, wherein the symbol A is a single bond or vinylene group which is unsubstituted or unsubstituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 68, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are defined in claim 1). 4-(p-Heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,3-benzodioxole or sodium salt thereof. A compound according to claim 2, wherein the symbol B is a benzene ring (i.e. the formula: A compound according to claim 71, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 72, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). 8-[p-(4-Phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)naphthalene, or 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl) methoxynaphthalene; or a sodium salt thereof. A compound according to claim 2, wherein the symbol B is a 2,3,6,7-tetrahydro-5H-1,4-dioxepin ring (i.e. the formula: A compound according to claim 75, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 76, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). 9-[p-(2E,7-Octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-3,4-dihydro-2H-1,5-benzodioxepin or sodium salt thereof. A compound according to claim 2, wherein the symbol B is a morpholine ring (i.e. the formula: A compound according to claim 79, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atoms(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 80, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). 8-[p-(4-Phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-2,3-dihydro-1,4-benzoxazine or sodium salt thereof. A compound according to claim 2, wherein the symbol B is a 3,4,5,6-tetrahydro-2H-pyran ring (i.e. the formula: A compound according to claim 83, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A compound according to claim 84, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). 8-[p-(4-Phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-3,4-dihydro-2H-1-benzopyran or sodium salt thereof. A process for the preparation of a fused aminophenyl derivative of the general formula: [wherein A, B, R¹, R², R³ and R⁴ are as defined in claim 1], or a non-toxic salt thereof, which process is characterized by reacting an acid of general formula: R¹-A-COOH (II) (wherein A and R¹ are as defined in claim 1), or a corresponding dithioic acid, and a compound of general formula: (wherein B, R², R³, and R⁴ are as defined in claim 1), to form an amide-bond; and further, effecting saponification and/or esterification, if desired. A process for the preparation of a fused aminophenyl derivative of general formula: (wherein R²⁰ represents a methylene group or a single bond, and the other symbols are as defined in claim 1), or a non-toxic salt thereof; which process is characterized by reacting a compound of general formula: (wherein R²⁰ is as defined above, and the other symbols are as defined in claim 1), and an azide; and further, effecting salt formation, if desired. A process for the preparation of a fused aminophenyl derivative of general formula: (wherein R²⁰ represents a methylene group or a single bond, R⁵⁵ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), and T, A, R¹ and R³ are as defined in claim 1), or a non-toxic salt thereof; which process is characterized by reacting a compound of general formula: (wherein T, A, R¹ and R³ are as defined in claim 1), and a compound of general formula: (wherein X¹⁰ and X²⁰ represent halogen atoms, respectively, R⁵⁰ represents a straight or branched alkyl group of from 1 to 6 carbon atom(s), and R²⁰ represents a methylene group or a single bond); and further effecting saponification and/or esterification, if desired. A pharmaceutical composition characterised by comprising as active ingredient at least one compound of the general formula (I) as defined in any one of claims 1 to 86, or a non-toxic salt thereof, together with a pharmaceutical carrier and/or coating. A compound of general formula (I), as defined in claim 1 or a non-toxic salt thereof for use as a medicament, for the prevention and/or treatment of tracheal, bronchial or lung diseases such as asthma or allergic disease. The use of a compound of general formula (I), as defined in claim, 1 or a non-toxic salt thereof, for the manufacture of a medicament for the prevention and/or treatment of trachial, bronchial or lung diseases such as asthma or allergic disease. Claims for the following Contracting State : AT A process for the preparation of a fused aminophenyl derivative of the general formula: [wherein symbol A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethylene group optionally being substituted by one, two or three straight or branched alkyl groups(s) of from 1 to 10 carbon atom(s) and/or phenyl groups(s), symbol B represents a carbocyclic ring of from 4 to 8 members wherein one, two or three of the carbon atom(s) may be replaced by oxygen, nitrogen and/or sulphur atom(s), or wherein the ring may optionally be substituted by group(s) of oxo, thioxo, and/or hydroxy group(s), symbol T represents an oxygen atom or a sulphur atom, R¹ represents a group of formula: (i) (ii) or (iii) or (iv) a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s), (wherein R⁵ and R⁶ independently represent a hydrogen atom or a halogen atom or a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s) wherein one, two, three, four or five of the carbon atom(s) may be replaced by oxygen atom(s), sulphur atom(s), halogen atom(s), nitrogen atom(s), benzene ring(s), thiophene ring(s), naphthalene ring(s), carbocyclic ring(s) of from 4 to 7 carbon atom(s), carbonyl group(s), carbonyloxy group(s), hydroxy group(s), carboxy group(s), azido group(s) and/or nitro group(s)), R² represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), R³ represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: -COOR⁷ (wherein R⁷ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s)) or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s), and R⁴ represents a group of general formula: -U-(CH₂) n -COOR⁸ -U-(CH₂) p -COOR⁸ or (wherein symbol U represents an oxygen atom or a sulphur atom, R⁸ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), n and m represent an integer of from 1 to 10, respectively, and p and q represent zero or an integer of from 1 to 10, respectively)]; or a non-toxic salt thereof which process is characterized by reacting an acid of general formula: R¹-A-COOH (II) (wherein A and R¹ are as defined in claim 1), or a corresponding dithioic acid, and a compound of general formula: (wherein B, R², R³, and R⁴ are as defined in claim 1), to form an amide-bond; and further, effecting saponification and/or esterification, if desired. A process for the preparation of a fused aminophenyl derivative of general formula: (wherein R²⁰ represents a methylene group or a single bond, and the other symbols are as defined in claim 1), or a non-toxic salt thereof; which process is characterized by reacting a compound of general formula: (wherein R²⁰ is as defined above, and the other symbols are as defined in claim 1), and an azide; and further, effecting salt formation, if desired. A process for the preparation of a fused aminophenyl derivative of general formula: (wherein R²⁰ represents a methylene group or a single bond, R⁵⁵ represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), and T, A, R¹ and R³ are as defined in claim 1), or a non-toxic salt thereof; which process is characterized by reacting a compound of general formula: (wherein T, A, R¹ and R³ are as defined in claim 1), and a compound of general formula: (wherein X¹⁰ and X²⁰ represent halogen atoms, respectively, R⁵⁰ represents a straight or branched alkyl group of from 1 to 6 carbon atom(s), and R²⁰ represents a methylene group or a single bond); and further effecting saponification and/or esterification, if desired. A process according to claim 1 or 2, wherein the symbol B is a ring of formula: (the rings may optionally be substituted by hydroxy group(s).) A process according to claim 3 or 4, wherein the symbol B is 2,3,5,6-tetrahydro-1,4-dioxane ring (i.e the formula: A process according to claim 3 or 5, wherein the symbol A is a single bond, and the symbol T is an oxygen atom. A process according to claim 6, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). A process according to claim 8, wherein the compound is 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-(p-isooctyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A compound according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkenyloxy group of from 3 to 19 carbon atoms. A process according to claim 10, wherein the compound is 8-[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2Z-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-nonenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(3E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(2E-octenyloxy)benzoyl]amino-1,4-benzodioxane-2-carboxylic acid or methyl ester thereof, 8-[p-(2E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-(p-geranyloxy benzoyl)amino-2-(5-tetrazoyl)-1,4-benzodioxane, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(2E,4E-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkynyloxy group of from 3 to 19 carbon atoms. A process according to claim 12, wherein the compound is 8-[p-(2-octynyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(2-isooctynyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkylthio group of from 1 to 19 carbon atom(s). A process according to claim 14, wherein the compound is 8-(p-heptylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). A process according to claim 16, wherein the compound is 8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(5-chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(4-chlorobutoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(9-chlorononyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4 benzodioxane; or a sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a phenyl, phenylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkenyloxy (wherein alkenyl moiety is a group of from 2 to 8 carbon atoms), napthyl, napthylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), napthylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s) ) or napthylalkenyloxy group (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) being unsubstituted or substituted by a straight or branched alkyl group of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). A process according to claim 18, wherein the compound is 8-[p-(p-propylphenyl)methoxybenzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy, alkenyloxy or alkoxyalkoxy group of from 1 to 18 carbon atom(s) wherein carbon atom(s) is/are replaced by carbonyl group(s), carbonyloxy group(s) or hydroxy group(s). A process according to claim 20, wherein the compound is 8-(p-octanoylbenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 17 carbon atom(s) being substituted by a phenoxy or phenylthio group. A process according to claim 22, wherein the compound is 8-[p-(3-phenylthiopropoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(3-phenoxypropoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). A process according to claim 24, wherein the compound is 8-[p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 7, wherein R⁵ is a hydrogen atom and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by azido group(s), nitro group(s) or amino group(s) which are unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) (including dialkylamino group). A process according to claim 26, wherein the compound is 8-[p-(5-azidopentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 3 or 5, wherein the symbol A is a vinylene group unsubstituted or substituted by straight or branched alkyl group(s), and the symbol T is an oxygen atom. A process according to claim 28, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 29, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). A process according to claim 30, wherein the compound is 8-(p-isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 29, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). A process according to claim 32, wherein the compound is 8-[p-(4-chlorobutoxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, or 8-[p-(5-chloropentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane; or a sodium salt thereof. A process according to claim 29, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkyloxyalkyl group of from 2 to 19 carbon atoms. A process according to claim 34, wherein the compound is 8-(p-isopentyloxymethylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 29, wherein R⁵ is a hydrogen atom, and R⁶ is a phenyl, phenylalkyl (wherein alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)) or phenylalkenyloxy (wherein the alkenyl moiety is a group of from 2 to 8 carbon atom(s)) being unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). A process according to claim 36, wherein the compound is 8-[p-(2-phenylethoxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 29, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). A process according to claim 38, wherein the compound is 8-[p-[2-(2-thienyl)ethoxy]cinnamoyl]-amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 3 or 5, wherein the symbol A is a single bond or vinylene group, and the symbol T is a sulphur atom. A process according to claim 40, wherein the compound is 8-(p-heptyloxybenzothioyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane or sodium salt thereof. A process according to claim 4, wherein the symbol B is 4-oxo-2,3-dihydro-4H-1-pyran ring (i.e. the formula: A process according to claim 42, wherein the symbol A is a single bond, and the symbol T is an oxygen atom. A process according to claim 43, wherein R¹ is a group of general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a hydrogen atom or a straight or branched alkyl group of from 1 to 20 carbon atom(s). A process according to claim 45, wherein the compond is 8-(p-heptylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-octylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-(p-nonylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). A process according to claim 47, wherein the compound is 8-(p-butoxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-6-fluoro-4-oxo-4H-1-benzopyran, 8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkenyloxy group of from 3 to 19 carbon atoms. A process according to claim 49, wherein the compound is 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-geranyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-fluoro-4-oxo-4H-1-benzopyran, 8-[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-chloro-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkynyloxy group of from 3 to 19 carbon atoms. A process according to claim 51, wherein the compound is 8-[p-(2-octynyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran or sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). A process according to claim 53, wherein the compound is 8-[p-(5-chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, or 8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is phenyl, phenylalkyl (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), phenylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s).), phenylalkenyloxy (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) naphthyl, naphthylalkyl (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), naphthylalkyloxy (wherein the alkyl moiety is a group of from 1 to 8 carbon atom(s)), or naphthylalkenyloxy group (wherein the alkenyl moiety is a group of from 2 to 8 carbon atoms) being unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 8 carbon atom(s), hydroxy group(s), halogen atom(s) and/or nitro group(s). A process according to claim 55, wherein the compound is 8-[p-(3-phenylpropoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(3-phenyl-2E-propenyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 44, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by thiophene ring(s). A process according to claim 57, wherein the compound is 8-[p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5-tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 42, wherein the symbol A is a vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 59, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 60, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 19 carbon atom(s). A process according to claim 61, wherein the compound is 8-(p-isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran or sodium salt thereof. A process according to claim 60, wherein R⁵ is a hydrogen atom, and R⁶ is a straight or branched alkoxy group of from 1 to 18 carbon atom(s) being substituted by halogen atom(s). A process according to claim 63, wherein the compound is 8-[p-(5-chloropentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, or 8-[p-(6-chlorohexyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran; or a sodium salt thereof. A process according to claim 4, wherein the symbol B is a pyridine ring optionally substituted by hydroxy group(s) (i.e. the formula: A process according to claim 65, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 66, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 67, wherein the compound is 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-quinoline, or 8-[p-(4-phenylbutoxy)benzoyl]amino-4-hydroxy-2-(5-tetrazolyl)-quinoline; or a sodium thereof A process according to claim 4, wherein the symbol B is 4,5-dihydrodioxole ring (i.e. the formula: A process according to claim 69, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 70, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are defined in claim 1). A process according to claim 71, wherein the compound is 4-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,3-benzodioxole or sodium salt thereof. A process according to claim 4, wherein the symbol B is a benzene ring (i.e. the formula: A process according to claim 73, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 74, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 75, wherein the compound is 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)naphthalene, or 8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl) methoxynaphthalene; or a sodium salt thereof. A process according to claim 4, wherein the symbol B is a 2,3,6,7-tetrahydro-5H-1,4-dioxepin ring (i.e. the formula: A process according to claim 77, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 78, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 79, wherein the compound is 9-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-3,4-dihydro-2H-1,5-benzodioxepin or sodium salt thereof. A process according to claim 4, wherein the symbol B is a morpholine ring (i.e. the formula: A process according to claim 81, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atoms(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 82, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 83, wherein the compound is 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-2,3-dihydro-1,4-benzoxazine or sodium salt thereof. A process according to claim 4, wherein the symbol B is a 3,4,5,6-tetrahydro-2H-pyran ring (i.e. the formula: A process according to claim 85, wherein the symbol A is a single bond or vinylene group which is unsubstituted or substituted by straight or branched alkyl group(s) of from 1 to 6 carbon atom(s) or phenyl group(s), and the symbol T is an oxygen atom. A process according to claim 86, wherein R¹ is a group of the general formula: (wherein R⁵ and R⁶ are as defined in claim 1). A process according to claim 87, wherein the compound is 8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-3,4-dihydro-2H-1-benzopyran or sodium salt thereof. A pharmaceutical composition or method of production thereof characterised by the provision as active ingredient at least one compound of the general formula (I) as defined in any one of claims 1 to 88, or a non-toxic salt thereof, together with a pharmaceutical carrier and/or coating. A compound of general formula (I), as defined in claim 1, or a non-toxic salt thereof for use as a medicament, for the prevention and/or treatment of tracheal, bronchial or lung diseases such as asthma or allergic disease. The use of a compound of general formula (I), as defined in claim 1, or a non-toxic salt thereof, for the manufacture of a medicament for the prevention and/or treatment of trachial, bronchial or lung diseases such as asthma or allergic diseases.

Inventors: ARAI YOSHINOBU, MIYAMOTO TUMORU, TODA MASAAKI, ARAI, YOSHINOBU, MIYAMOTO, TUMORU, TODA, MASAAKI
Applicants: ONO PHARMACEUTICAL CO, ONO PHARMACEUTICAL CO., LTD.
Application year: 1985
Main classification: C07D405
IPC codes: C07D401, C07D409, C07D405, C07D311, C07D257, C07D413, C07D319, C07D215, C07C233, C07C235, C07C323